3/6/2012 6:24:25 AM
BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) today announced the presentation of data from KALBITOR® (ecallantide) clinical studies in hereditary angioedema (HAE) at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in Orlando, Florida. The data were presented in four separate poster presentations and included data related to rebound and relapse rates in patients treated with KALBITOR as well as to KALBITOR for the treatment of acute laryngeal attacks of HAE. KALBITOR is indicated for the treatment of acute attacks of HAE in patients 16 years of age and older.
comments powered by